Coronavirus Drug Discovery

Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.

PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS  1. SARS-CoV-2 genome sequencing and promising druggable targets 2. Signaling pathways implicated in SARS-CoV2 infection 3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease 4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of Actions

PART 2: COMPUTATIONAL APPROACHES 5. Application of computational tools for coronavirus drug discovery 6. In silico Approaches in Drug Discovery for SARS-CoV-2 7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies 8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19  9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2  10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins  11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals 12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry